Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-ABY-025 Imaging in HER2+ Cancers
NCT06828588Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-ABY-025 in solid tumor, sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Adverse Events at 35 days. Started Apr 2026; status: recruiting.
02
Drugs
68Ga-ABY-025
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06828588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828588.